Foghorn Therapeutics Inc.

Industry

  • Biotechnology
    • Drug Discovery Technologies
  • Pharmaceuticals
    • Vaccines
See more in Biomedtracker

Latest on Foghorn Therapeutics Inc.

Scrip

Finance Watch: Cytokinetics Accesses Up To $1bn-Plus, Confirms No-Sale Plan

 
• By Mandy Jackson

Cytokinetics, Inc. CEO Robert Blum has maintained since the company reported positive topline Phase III results for the cardiac myosin inhibitor aficamten in obstructive hypertrophic cardiomyopathy (

Scrip

Foghorn’s AML/MDS Trial Moved From Partial To Full Clinical Hold

 
• By Mandy Jackson

Foghorn Therapeutics Inc. ’s lead drug candidate FHD-286 has the potential to treat both hematological malignancies and solid tumors, but its future in acute myeloid leukemia (AML) and myelodysplastic

Scrip

Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold

 
• By Alaric DeArment

Foghorn Therapeutics Inc. ’s development program for FHD-286 has run into trouble as the US Food and Drug Administration has placed a partial clinical hold in acute myeloid leukemia (AML) and myelodys

In Vivo

Rough Guide To Targeted Protein Degradation

 
• By Alex Shimmings

Targeted protein degradation, or TPD, has been steadily gaining attention in recent years as a highly promising new drug development strategy that has already attracted significant investment and big